uracil has been researched along with Blood Pressure, High in 18 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "0 g/kg food) provided significant protection against elevation of blood pressure and cardiac hypertrophy in male rats treated with desoxycorticosterone trimethylacetate (DTMA) (5." | 7.65 | Effect of some substituted pyrimidines on development of desoxycorticosterone-induced hypertension in rats. ( Fregly, MJ; Rubin, ML, 1977) |
| "Urapidil was found effective in the treatment of hypertension during extracorporeal circulation." | 6.65 | Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine. ( Barankay, A; Göb, E; Richter, JA, 1981) |
| "0 g/kg food) provided significant protection against elevation of blood pressure and cardiac hypertrophy in male rats treated with desoxycorticosterone trimethylacetate (DTMA) (5." | 3.65 | Effect of some substituted pyrimidines on development of desoxycorticosterone-induced hypertension in rats. ( Fregly, MJ; Rubin, ML, 1977) |
| "Conclusions In patients with type 2 diabetes mellitus and recent acute coronary syndrome, average BP s <130/80 mm Hg were associated with worsened cardiovascular outcomes." | 2.87 | Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. ( Bakris, GL; Bergenstal, R; Cannon, CP; Cushman, WC; Heller, SR; Jalil, F; Liu, Y; Mehta, C; White, WB; Zannad, F, 2018) |
| "Urapidil was found effective in the treatment of hypertension during extracorporeal circulation." | 2.65 | Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine. ( Barankay, A; Göb, E; Richter, JA, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Wiegand, J | 1 |
| Buggisch, P | 1 |
| Mauss, S | 1 |
| Boeker, KHW | 1 |
| Klinker, H | 1 |
| Müller, T | 1 |
| Günther, R | 1 |
| Serfert, Y | 1 |
| Manns, MP | 1 |
| Zeuzem, S | 1 |
| Berg, T | 1 |
| Hinrichsen, H | 1 |
| C-Registry, GH | 1 |
| Fan, SH | 1 |
| Xiong, QF | 1 |
| Wang, L | 1 |
| Zhang, LH | 1 |
| Shi, YW | 1 |
| Wang, J | 1 |
| Fan, S | 1 |
| Xiong, Q | 1 |
| Niu, Y | 1 |
| Zhang, X | 1 |
| Qin, J | 1 |
| Shi, Y | 1 |
| Zhang, L | 1 |
| White, WB | 1 |
| Jalil, F | 1 |
| Cushman, WC | 1 |
| Bakris, GL | 1 |
| Bergenstal, R | 1 |
| Heller, SR | 1 |
| Liu, Y | 1 |
| Mehta, C | 1 |
| Zannad, F | 1 |
| Cannon, CP | 1 |
| Kishimoto, S | 1 |
| Kinoshita, Y | 1 |
| Matsumoto, T | 1 |
| Maruhashi, T | 1 |
| Kajikawa, M | 1 |
| Matsui, S | 1 |
| Hashimoto, H | 1 |
| Takaeko, Y | 1 |
| Kihara, Y | 1 |
| Chayama, K | 1 |
| Goto, C | 1 |
| Mohamad Yusoff, F | 1 |
| Nakashima, A | 1 |
| Noma, K | 1 |
| Higashi, Y | 1 |
| Liu, YY | 1 |
| Zeng, SY | 1 |
| Leu, YL | 1 |
| Tsai, TY | 1 |
| Nishimura, A | 1 |
| Nishida, M | 1 |
| CANELLAKIS, ES | 1 |
| Barankay, A | 2 |
| Göb, E | 2 |
| Richter, JA | 2 |
| Fischer, R | 1 |
| Haerlin, R | 1 |
| Steinijans, V | 2 |
| Zech, K | 1 |
| Bruckschen, EG | 2 |
| Sumi, S | 1 |
| Kidouchi, K | 1 |
| Hayashi, K | 1 |
| Imaeda, M | 1 |
| Asai, M | 1 |
| Wada, Y | 1 |
| Fregly, MJ | 1 |
| Rubin, ML | 1 |
| Henze, F | 1 |
| Michael, G | 1 |
| Schoetensack, W | 1 |
| Bischler, P | 1 |
| Dittmann, EC | 1 |
| Salvati, P | 1 |
| Vaghi, F | 1 |
| Colombo, M | 1 |
| Bianchi, G | 1 |
| Hueber, EF | 1 |
| Stupnitskiĭ, AA | 1 |
| Golikov, BM | 1 |
| Apanasenko, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
1 review available for uracil and Blood Pressure, High
| Article | Year |
|---|---|
Purinergic signaling in cardiovascular system.
Topics: Adenosine; Animals; Cardiovascular System; Humans; Hypertension; Risk Factors; Signal Transduction; | 2017 |
3 trials available for uracil and Blood Pressure, High
| Article | Year |
|---|---|
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.
Topics: Aged; Analysis of Variance; Blood Pressure Determination; Cause of Death; Diabetes Mellitus, Type 2; | 2018 |
Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine.
Topics: Aged; Anesthesia; Antihypertensive Agents; Cardiopulmonary Bypass; Hemodynamics; Humans; Hypertensio | 1981 |
[Clinical trials of urapidil. Review of human pharmacological studies with a summary of a multi-center study].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Electrophysiology; Femal | 1978 |
14 other studies available for uracil and Blood Pressure, High
| Article | Year |
|---|---|
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Car | 2019 |
Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway.
Topics: Animals; Blood Pressure; Cells, Cultured; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Gene | 2020 |
Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways.
Topics: Adenylate Kinase; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Pressure; Cardiome | 2021 |
Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Arterial Pressure; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2019 |
Antihypertensive Effect of a Combination of Uracil and Glycerol Derived from Lactobacillus plantarum Strain TWK10-Fermented Soy Milk.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Antioxidants; Drug Thera | 2015 |
Pyrimidine metabolism. III. The interaction of the catabolic and anabolic pathways of uracil metabolism.
Topics: Hypertension; RNA; Uracil | 1957 |
Treatment of hypertension in coronary bypass surgery. Clinical experience with urapidil.
Topics: Adult; Aged; Coronary Artery Bypass; Dose-Response Relationship, Drug; Hemodynamics; Humans; Hyperte | 1981 |
Preliminary results on the correlation between serum level and antihypertensive effect of urapidil (Ebrantil).
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Male; Piperazines; Time Factors; Uraci | 1981 |
Urinary screening for pyrimidine metabolism disorders. Reference ranges for dihydrouracil, uracil, and dihydrouracil/uracil ratio.
Topics: Adult; Cerebral Infarction; Dihydrouracil Dehydrogenase (NADP); Female; Humans; Hypertension; Liver | 1998 |
Effect of some substituted pyrimidines on development of desoxycorticosterone-induced hypertension in rats.
Topics: Animals; Body Weight; Cardiomegaly; Desoxycorticosterone; Hematocrit; Hemoglobins; Hypertension; Mal | 1977 |
[Studies on the influence of the antihypertensive drug urapidil on blood circulation and its regulation in animal experiments (author's transl)].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Carotid Sinus; Cats; Dogs; Efferen | 1977 |
A new selective antagonist of vascular serotonin receptors lowers blood pressure in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Ergolines; Hypertension; In Vitro Techniq | 1988 |
[Treatment of arterial hypertension with new drugs. 2. Moderate arterial hypertension: 4-aminouracil-phenylpiperazine].
Topics: Humans; Hypertension; Piperazines; Uracil | 1972 |
[Mechanism of changes in the duration of the phase of asynchronous contraction in patients with hypertensive disease and atherosclerosis].
Topics: Adult; Aged; Antihypertensive Agents; Coronary Disease; Female; Guanethidine; Heart; Humans; Hyperte | 1971 |